Mode
Text Size
Log in / Sign up
Phase 4 N=180 Randomized Double-blind Basic Science

New Stage 1 Formula on Gut Comfort and Gut Health

Health Behavior

Enrolled (actual)
180
Serious AEs
0.0%
Results posted
Oct 2016
Primary outcome: Primary: Stool Frequency — 2.2; 2.2; 2.3; 1.6 Times per day

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Oral intake of Feihe New Formula (Dietary_supplement); Oral intake of Feihe Stage 1 Formula (Dietary_supplement); Breast Feeding (Dietary_supplement)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
Heilongjiang Feihe Dairy Co. Ltd.
Primary completion
Aug 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Stool Frequency
2.2; 2.2; 2.3; 1.6; 1.8; 2.1
SECONDARY
Number of Participants With Gastrointestinal Symptoms
0; 0; 0
SECONDARY
Stool Consistency
3.61; 3.74; 3.76; 3.19; 3.59; 3.73
SECONDARY
Crying Time
2.98; 2.90; 2.92; 3.43; 2.69; 2.62
SECONDARY
Fecal Concentration of Short Chain Fatty Acid
4.66; 4.75; 4.72; 1.28; 1.27; 1.33
SECONDARY
Body Length
56.9; 57.7; 57.8; 60.3; 60.8; 61.1
SECONDARY
Number of Participants With Eczema
15; 9; 8
SECONDARY
Fecal Laboratory Detection for sIgA
53.8; 53.0; 55.5; 55.3; 62.7; 65.9
SECONDARY
Fecal Bacterium Concentration
7.56; 7.55; 7.58; 6.61; 6.58; 6.63
SECONDARY
Eczema Duration
62.1; 45.2; 38.6
SECONDARY
Body Weight
5191.5; 5291.5; 5462.1; 6142.4; 6251.7; 6370.7
SECONDARY
Head Circumference
38.5; 38.7; 39.0; 39.9; 40.1; 40.4
SECONDARY
Chest Circumference
36.9; 37.2; 37.3; 38.2; 38.6; 38.7
SECONDARY
Milk Regurgitation Frequency
2.68; 2.47; 2.43; 2.70; 2.02; 1.89
SECONDARY
Milk Feeding Quantity
732.1; 742.2; 750.7; 928.6; 936.3; 946.0
SECONDARY
Sleeping Time
18.0; 17.8; 17.9; 17.6; 17.4; 17.6
SECONDARY
Body Mass Index (BMI)
15.9; 15.8; 16.2; 16.9; 16.9; 17.0

Summary

180 qualified subjects aged from 7 days to 90 days will be enrolled with the 144 completed in study (allowing for a 20% drop-out rate). Subjects will be randomly assigned into 3 groups, including breast feeding, commercial and new formula group. Study intervention is 12 weeks.

Eligibility Criteria

Inclusion Criteria

  • Infants aged 7-90 days;
  • Fed by breast milk before enrollment;
  • Parent or legal guardian fully understand the purpose and requirement, including the potential risks and side effects of the study;
  • Willing to participate in the study and comply all the procedures;
  • Concent form signed by parents.

Exclusion Criteria

  • Twins, multiple birth, low birth weight children, over birth weight children or early birth children with gestational age less than 37 weeks;
  • Think about the need to exclude C-section delivered infants? It's often the majority of births in Chinese tier-1 cities, so it will probably make the study recruitment slower, and postpone the study. The microflora of C-section infants in known to be different compared to normally born infants. At least, the mode of delivery should be noted and calculated into the primary and secondary outcome measurements as a potential confounding factor
  • During pregnancy, the mothers had pregnancy complications or other disease that may affect the results;
  • Having serious diseases that may affect study interventions, such as neonatal sepsis, pneumonia (associated with respiratory failure), heart failure and other disease;
  • Having neonatal diarrhea or acute respiratory infections within 48hours before enrollment;
  • Having potential metabolic diseases, chronic diseases, congenital malformations, central nervous system disorders, neuromuscular disorders or diseases affecting bone metabolism that may affect growth or the study results;
  • Having taken any food containing prebiotics or probiotics tithing 15 days of enrollment;
  • Having gluten allergy (celiac disease);
  • Body weight-to-height Z-value<-3 according to the standard of WHO;
  • Receiving hormone therapy and intravenous nutrition;
  • Lactose intolerance or allergic to ingredients of study product;
  • Have participated in other clinical studies within 3 months prior to the date of screening;
  • Unable to comply the study schedule.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02406937). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search